Interaction of a Plasmin A-Chain/t-PA B-Chain Hybrid Enzyme with Plasma Inhibitors In Vivo and In Vitro

Summary

A hybrid plasminogen activator consisting of the “A” chain of plasmin linked to the “B” chain of rt-PA was inhibited in vitro in human and guinea pig plasmas 4 to 5-fold more rapidly than its parent activator, two-chain t-PA. Using zymographic and autoradiographic techniques together with the use of immunodepleted plasma the major inhibitor was identified as aIpha-2-antiplasmin. The pharmacokinetic profile of the hybrid in guinea pigs was determined by two different methods: disappearance of fibrinolytic activity and removal of radiolabelled hybrid from the circulation. Fibrinolytic activity was cleared rapidly via inhibitory mechanisms, whilst radiolabelled material was cleared considerably more slowly due to the formation of hybrid-inhibitor complexes. When the active site of the hybrid was reversibly acylated inhibitory mechanisms were evaded and a prolonged pharmacokinetic profile of activity was observed.

• References

• 1 Robinson JH, Dodd I, Esmail A, Ferres H, Nunn B. Slow clearance of acylated, hybrid thrombolytic enzymes. Thromb Haemostas 1988; 59: 421-5
• 2 Browne MJ, Carey JE, Chapman CG, Tyrrell AW R, Entwisle C, Lawrence GM P, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602
• 3 Browne MJ, Champan CG, Dodd I, Reavy B, Esmail A, Robinson JH. The role of tissue-type plasminogen activator A-chain domains in plasma clearance. Fibrinolysis 1989; 3: 207-14
• 4 Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-50
• 5 Fu KP, Lees S, Hum WT, Kalyan N, Rappaport R, Hetzel N, Hung PP. Disposition of a novel recombinant tissue plasminogen activator, Δ2-89 t-PA, in mice. Thromb Res 1988; 50: 33-41
• 6 Fu PP, Lee S, Hetzel N, Fenichel R, Hum HW, Speth J, Kalyan N, Hung PP. Clearance of a novel recombinant tissue plasminogen activator in rabbits. Thromb Res 1988; 50: 679-85
• 7 Mohler MA, Tate K, Bringman TS, Fuller G, Keyt B, Vehar G, Hotchkiss AJ. Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits. Fibrinolysis 1988; 2: 17-23
• 8 Seifried E, Tanswell P, Rijken DC, Barrett-Bergshoeff MM, Su C AP F, Kluft C. Pharmacokinetics of antigen and activitv of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneim Forsch 1988; 38: 418-22
• 9 Browne MJ, Dodd I, Carey JE, Chapman cG, Robinson JH. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology. Thromb Haemostas 1985; 54: 422-4
• 10 Dodd I, Fears R, Robinson JH. Isolation and preliminary characterisation of active B-chain of recombinant tissue-type plasminogen activator. Thromb Haemostas 1986; 55: 94-7
• 11 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide 1, 3, 4, 6-tetrachloro-3 a, 6a-Dipheny-Iglycoluril. Biochem Biophys Res Commun 1978; 80: 849-57
• 12 Lacmmli UK. Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature 1970; 227: 680-5
• 13 Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34
• 14 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-7
• 15 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8
• 16 Haggroth L, Mattsson Ch, Friberg J. Inhibition of the tissue plasminogen acctivator in plasma from different species. Thromb Res 1984; 33: 583-94
• 17 Korninger C, Collen D. Neutralisation of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor. Thromb Haemostas 1981; 46: 662-5
• 18 The AIMS trial Study Group. Effect of intravenosus APS AC on mortality after acute myocardial infarction. Preliminary report of a placebo-controlled trial. Lancet 1988; i: 545-9